Benda Pharmaceutical Inc.(fka BPMA)

[Alyssa]

It's hard to say re: Pope. But SiBiono appears to be alive and well and quite busy, and they're continuing to work on expanding their gene therapy to the international markets with cooperative agreements, etc. And their website contains other recent news from February and March of 2013.

The sonorous international place

To enter the international market, and actively carry out international cooperation, as a global leader in gene therapy companies race Benro an important part of the implementation of the international strategy in recent years. SiBiono since 2008 to enter the international market, one step at a time, the expansion of the international market has made gratifying achievements.
Enter the international market and extend our world collaboration is a major theme in our globalization for our gene therapy drive. Sibiono has officially entered the global market since 2008. The footsteps are small but impressive on the market share return.

2008, SiBiono India and Pakistan more than a dozen Muslim countries to the ? recombinant human adenovirus p53 injection ? drug registration and clinical research work, the signing of the cooperation agreement, the reporting of clinical trials, to jointly develop gene therapy market.
In June 2009, SiBiono and Canada, the North American gene diagnosis and treatment Co., Ltd. signed a cooperation agreement to work together to expand the Philippines and Southeast Asia market.
In September 2009, SiBiono cooperation with the Japanese Association Gendicine "gene therapy services for cancer patients in Japan.
In January 2010, the SiBiono with Taiwan well-known pharmaceutical companies formally signed a cooperation agreement, the successful opening of the cancer treatment market, and enjoys the reputation of "the mother of the Taiwan Cancer Whang-Peng academicians powerful combination, to conduct a joint cross-strait tumor gene treatment.
In March 2010, SiBiono and Brazil signed a cooperation agreement to join hands to declare "Gendicine" Registration Approval in Brazil, and the joint development of the South American gene therapy market.
In March 2010, SiBiono and the Philippines signed a cooperation agreement to jointly promote gene therapy in the Philippines, local rooting, flowering results.
In March 2011, SiBiono signed an agreement with Malaysian partners, and to expand the gene therapy markets in Malaysia, Singapore. November 27, SiBiono successfully held in Kuala Lumpur International Symposium session keynote for gene therapy, and in cooperation with the Malaysian investors on Gendicine "the official sales agent in Malaysia held a signing ceremony.
In December 2011, SiBiono partner with the United States signed an agreement to work together to open up the U.S. gene therapy market.
March 2010, March-December 2011, SiBiono in Shenzhen, China, Dubai, United Arab Emirates, Manila, Philippines, China, Hong Kong and Kuala Lumpur, Malaysia, organized 5 international clinical application of gene therapy of cancer seminar will be from Switzerland, Germany, Canada, Japan, the Philippines, Malaysia, Indonesia, Singapore and other countries, as well as the Chinese mainland, Hong Kong and Taiwan experts and gene cancer treatment drug research experts nearly a thousand people to ride the event.

2008 Sibiono signed collaboration agreement with India, Pakistan and more than 10 other Muslim countries for clinical research, drug registration and marketing on 'rAd-p53, Inj'.
2009.6 Sibiono and Canadian N. America Gene Diagnostics & Therapy Co., Ltd. Signed an agreement on the joint effort in opening up the Philippino and SE Asian market.
2009.9 Sibiono collaborated with a Japanese organization on providing Gendicine ® gene therapy tor cancer patients in Japan.
2010.1 Successfully open up the Taiwan cancer treatment market in collaboration with a prominent Taiwan Enterprise. Built up a cross-strait tumor gene therapy with the strong collaboration of Dr WJ Huang, (a member of Chinese Academy of Science, Taiwan, she is also honored as 'mother of Taiwan Cancer Specialty.'
2010.2 Signed an agreement with Rothschild Group on gene therapy market development in Europe.
2010.3 Signed collaborative agreement with the Philippines on gene therapy for local use and further development.
2010.3 Signed collaborative agreement with Brazil on the joint effect in applying registration and setting up South America gene therapy market.
2011.3 Signed an agreement with the Malaysia collaboration partner for the development of Singapore-Malaysia gene therapy market.
2011.11.27 Successfully sponsored an international symposium on gene therapy at Kuala Lumpur. The Malaysia partner invested and agreed as a Gendicine ® representative there.
2011.12 Signed a partnership agreement with an America partner for the market development in gene therapy in the USA.
2010.3 & 2011.3-12 Sibiono held gene therapy clinical application symposia in Shenzhen, Dubai-United Arab Emirates, the Philippines, Hong Kong, Kuala Lumpur. The participants were experts in oncologists and gene therapy drugs totaling near 1000 coming from Switzerland, Germany, Canada , Japan, and SE Asian countries. (2012.2)


http://translate.googleusercontent.com/translate_c?depth=1&ei=LkNhUZq1BsKB0AHew4DYAg&hl=en&prev=/search%3Fq%3DShenzhen%2BSiBiono%26hl%3Den%26client%3Dfirefox-a%26hs%3D76S%26rls%3Dorg.mozilla:en-US:official&rurl=translate.google.com&sl=zh-CN&u=http://www.sibiono.com/news/15984512.html&usg=ALkJrhg9uuePbLUH7RT0tiLcnv06SOST3Q